Evidence map›Paper›PMID 33688344›Full record

ArticleInternational journal of endocrinology2021

Impact of the 8

Riccardo Maggiore, Francesca Perticone, Gilberto Mari, Riccardo Pasquali, Emanuele Bosi, Marina Scavini, Roberto Lanzi, Riccardo Rosati

Open access · goldAbstract read
In one paragraph

Article in International journal of endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Riccardo MaggioreEndocrine Unit, Department of Surgery, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.ORCID https://orcid.org/0000-0002-2869-9859
Francesca PerticoneEndocrine Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Gilberto MariEndocrine Unit, Department of Surgery, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Riccardo PasqualiEndocrine Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Emanuele BosiEndocrine Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Marina ScaviniEndocrine Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Roberto LanziEndocrine Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Riccardo RosatiEndocrine Unit, Department of Surgery, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
Vita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe 8

methodsWe retrospectively reviewed the medical records of 172 patients that from January 1

results101 out of 172 patients (58.7%) were reallocated to a lower stage. Of the 101 downstaged patients, 88 (88.9%) showed a high or intermediate American Thyroid Association (ATA) risk of recurrence. We recorded no cancer-specific deaths.

conclusionsRisk of cancer-specific mortality in patients aged 45-54 years with DTC is low, supporting the prognostic capability of the 8

Identifiers

PMID33688344
PMCPMC7920729
OpenAlexW3131801178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.